This VJHemOnc podcast explores how BTK inhibitor therapy can be personalized for patients with chronic lymphocytic leukemia (CLL), considering disease biology, patient characteristics and treatment goals.

Kerry Rogers, MD, The Ohio State University, Columbus, OH, discusses frontline treatment selection, molecular risk and factors influencing BTK inhibitor choice, while Florian Simon, MD, University Hospital Cologne, Cologne, Germany, examines cardiovascular toxicity and treatment considerations in older patients and those with comorbidities. Dima El-Sharkawi, MB, BS, MA, PhD, MRCP, FRCPath, The Royal Marsden NHS Foundation Trust, London, UK, discusses quality of life and shared decision-making, and Gianluca Gaidano, MD, PhD, University of Eastern Piedmont, Vercelli, Italy, explores BTK inhibitor selectivity, safety and treatment options following covalent BTK inhibitor failure.

In this episode of the VJHemOnc podcast, leading experts discuss key advances in multiple myeloma presented at the 23rd Annual Meeting and Exposition of the International Myeloma Society (IMS 2026), held in Glasgow, UK. Pieter Sonneveld reviews long-term progression-free survival outcomes from the Phase III PERSEUS trial (NCT03710603), while Zachary Avigan explores the potential for treatment cessation in patients with sustained measurable residual disease (MRD) negativity and the evolving concept of cure. Rakesh Popat discusses emerging combination strategies at first relapse, and Luciano Costa examines the survival benefits of teclistamab plus daratumumab in the Phase III MajesTEC-3 trial (NCT05083169). Hermann Einsele highlights real-world and long-term outcomes with ciltacabtagene autoleucel (cilta-cel), Shaji Kumar discusses the Phase III CERVINO trial of etentamig, and Paul Richardson explores the evolving role of cereblon E3 ligase modulators (CELMoDs). Together, these experts consider how advances in immunotherapy, novel agents, and treatment sequencing may shape the future management of patients with multiple myeloma.

This episode of the VJHemOnc podcast features an exclusive expert-led roundtable discussion summarizing two sessions from the 8th International Workshop on Acute Leukemias (iwAL 2026) that focused on novel targets, combinations, and treatments in acute myeloid leukemia (AML). This session is chaired by Gail Roboz, MD, Weill Cornell Medicine, New York City, NY, who is joined by panelists Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, and Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France. The experts explore the evolving genetic classification of AML and the nuances of TP53, the move from azacitidine and venetoclax toward molecularly guided triplets, emerging strategies to overcome menin inhibitor resistance and target TP53-mutated disease, and the promise of an all-oral regimen in this malignancy.